Abera Bioscience develops next-generation nasal vaccines using a modular OMV platform that enables rapid design, cost-effective production and strong mucosal and systemic immunity.
Årsstämma 2026 i Abera Bioscience AB (”Abera” eller ”Bolaget”) hölls den 10 juni 2026. Ordförande Anders Ericson höll ett inledande anförande som också återfinnas längre
Abera Bioscience AB (“Abera” or the “Company”) today announces that GMP production of clinical trial material for the Company’s vaccine candidate Ab-01.12 – a first-in-class
Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT FÖRSTA KVARTALET 2026 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 3 553 (3 574) kSEK Resultatet efter finansiella poster
Abera Bioscience’s OMV platform enables rapid, modular vaccine design with high flexibility across disease targets. The technology supports efficient, scalable manufacturing and induces both mucosal and systemic immunity, making it suitable for seasonal, bacterial and emerging pathogens.
The pipeline includes a serotype-independent nasal pneumococcal vaccine preparing for Phase 1 and a nasal influenza vaccine progressing through preclinical development. The platform’s adaptability also provides opportunities for future programs within pandemic preparedness and additional infectious disease areas.
Abera’s platform is designed with global health in mind. Our OMV technology enables scalable, cost-effective vaccine production without eggs, using controlled liquid fermentation. Vaccines can be delivered as a simple nasal spray and have potential for powder formulation — reducing the need for needles, cold chain and complex logistics.
This makes our vaccines well suited for both high-income countries and low-resource settings.
Abera is dedicated to the development of novel vaccines to save lives and increase health globally.
